RUNX1 gene mutations are associated with adverse prognosis of patients with acute myeloidleukemia.
10.12122/j.issn.1673-4254.2020.11.10
- Author:
Yanli YANG
1
;
Tiantian LI
1
;
Yinghua GENG
1
;
Jun LI
1
Author Information
1. Department of Hematology, First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China.
- Publication Type:Journal Article
- Keywords:
RUNX1 gene;
acute myeloid leukemia;
gene mutation
- MeSH:
Core Binding Factor Alpha 2 Subunit/genetics*;
Humans;
Leukemia, Myeloid, Acute/genetics*;
Mutation;
Prognosis;
Remission Induction
- From:
Journal of Southern Medical University
2020;40(11):1601-1606
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the rate and distribution of Runt- related transcription factor 1 (RUNX1) gene mutations in patients with acute myeloid leukemia (AML) and the correlation of these mutations with the clinical characteristics and survival outcomes of the patients.
METHODS:The genomic DNA extracted from the bone marrow of 158 patients with newly diagnosed AML for PCR amplification of RUNX1 gene and sequence analysis to identify the mutations. The mutations of ASXL1, DNMT3A, TET2, FLT3, CEBPA, NPM1, IDH2, NRAS and c-KIT genes were also examined to analyze their association with RUNX1 gene mutations.
RESULTS:Among the 158 AML patients, 19 (12.0%) were found to have RUNX1 mutations in A166G (9 cases), A142T (6 cases) and A162L (4 cases). RUNX1 mutations were more frequent in elderly patients (
CONCLUSIONS:RUNX1 gene mutations are associated with an adverse prognosis of patients with AML.
